Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for Anixa Biosciences’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.40) EPS.

ANIX has been the topic of several other research reports. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Wednesday, January 22nd. Maxim Group began coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a “buy” rating and a $10.00 price objective for the company.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $3.08 on Tuesday. The business has a 50-day moving average of $2.96 and a 200-day moving average of $3.01. The company has a market capitalization of $99.17 million, a price-to-earnings ratio of -7.90 and a beta of 0.86. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). Research analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the transaction, the director now directly owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction on Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 75,289 shares of company stock worth $177,021 in the last quarter. 25.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new position in Anixa Biosciences in the fourth quarter valued at about $26,000. Focus Partners Wealth bought a new position in shares of Anixa Biosciences in the 4th quarter valued at about $162,000. Jane Street Group LLC acquired a new stake in shares of Anixa Biosciences during the 4th quarter worth approximately $67,000. Renaissance Technologies LLC grew its position in shares of Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after buying an additional 3,900 shares during the period. Finally, LPL Financial LLC raised its stake in shares of Anixa Biosciences by 37.2% during the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after buying an additional 11,633 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.